Publications by authors named "Senna Rayhi"
Background: Acute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF).
Aims: We aimed to compare the risk of major adverse cardiovascular events (MACE) in ACS patients presenting with known, newly diagnosed, or no AF.
Methods: In our multicentre, prospective registry study, we included patients with confirmed ACS.
Objective: Patients with acute coronary syndrome (ACS) remain at high risk for recurrent ischaemic and bleeding events during follow-up. Our study aimed to quantify and compare the impact of these adverse events on quality of life (QoL).
Methods: Data from patients with ACS prospectively enrolled in the FORCE-ACS registry between January 2015 and December 2019 were used for this study.
Article Synopsis
- The study aimed to assess the clinical efficacy and side effects of ticagrelor in patients with varying CYP3A5 gene status, specifically looking at thrombotic and bleeding events, as well as dyspnea.
- A total of 1,281 STEMI patients were genotyped, revealing no significant differences in thrombotic or bleeding outcomes between carriers and non-carriers of the gene, nor between CYP3A5 expressors and non-expressors.
- Overall, ticagrelor showed no statistical significance in affecting thrombotic events, bleeding rates, or dyspnea among the different genetic groups studied.
Objectives: To validate the Global Registry of Acute Coronary Events (GRACE) risk score and examine the extent and impact of the risk-treatment paradox in contemporary patients with acute coronary syndrome (ACS).
Methods: Data from 5015 patients with ACS enrolled in the FORCE-ACS registry between January 2015 and December 2019 were used for model validation. The performance of the GRACE risk score for predicting in-hospital and 1-year mortality was evaluated based on indices of model discrimination and calibration.